Krista F. Huybrechts, MS, PhD

  • 3Articles
  • 28.6KReads1
  • 2018–2023Active
  • 30Collaborators
  • 26Citations2

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

About

Krista F. Huybrechts, MS, PhD, is affiliated with the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital and Harvard Medical School. Her publications from 2018 to 2023 focus on the safety of psychiatric medications during pregnancy, including studies on atomoxetine, anticonvulsant mood stabilizers, lithium, and regulatory perspectives on reproductive safety. She frequently collaborates with researchers such as Brian T. Bateman and Helen Mogun.

Publications

JCP
Atomoxetine and Prevalence of Major Congenital Malformations
Original Research

Atomoxetine and Prevalence of Major Congenital Malformations

image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ January 16, 2023

Little is known about the safety of atomoxetine, a non-stimulant treatment for attention-deficit/hyperactivity disorder. This study assessed the prevalence of major congenital malformations after first-trimester exposure to atomoxetine.
, , , et al
JCP
Original Research

Mood Stabilizers and Placenta-Mediated Complications

June 18, 2019

Women who take mood stabilizers have a greater risk of placenta-mediated pregnancy complications. But are the mood stabilizers themselves responsible for this higher risk? This study explores that question.
, , , et al
JCP
Perspectives on the New FDA Pregnancy and Lactation Labeling Rule
Academic Highlights

Perspectives on the New FDA Pregnancy and Lactation Labeling Rule

July 17, 2018

Pregnancy labeling of prescription medications in the US is in the midst of a major transformation. Are you aware of the changes? Read this summary of a recent conference...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe